[{"address1": "Paasheuvelweg 25", "city": "Amsterdam", "zip": "1105 BP", "country": "Netherlands", "phone": "31 20 240 6000", "website": "https://www.uniqure.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.", "fullTimeEmployees": 480, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew Craig Kapusta CPA", "age": 52, "title": "CEO & Executive Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1017357, "exercisedValue": 0, "unexercisedValue": 96250}, {"maxAge": 1, "name": "Mr. Christian  Klemt", "age": 51, "title": "CFO, Principal Financial Officer & GM of Amsterdam Site", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 575462, "exercisedValue": 0, "unexercisedValue": 21000}, {"maxAge": 1, "name": "Mr. Richard  Porter Ph.D.", "age": 55, "title": "Chief Business & Scientific Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 732169, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeannette  Potts J.D., Ph.D.", "age": 62, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 635561, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Hugo  Katus", "title": "Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Amin  Abujoub Ph.D.", "title": "Chief Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tamara  Tugal Ph.D., MBA", "title": "Business Development Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Boyer", "title": "Chief People & Culture Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Walid  Abi-Saab M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Eileen  Sawyer", "title": "Vice President of Global Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 13.25, "open": 13.27, "dayLow": 13.25, "dayHigh": 14.24, "regularMarketPreviousClose": 13.25, "regularMarketOpen": 13.27, "regularMarketDayLow": 13.25, "regularMarketDayHigh": 14.24, "beta": 0.384, "forwardPE": -4.5040894, "volume": 583485, "regularMarketVolume": 583485, "averageVolume": 2295574, "averageVolume10days": 915350, "averageDailyVolume10Day": 915350, "bid": 14.13, "ask": 14.19, "bidSize": 200, "askSize": 200, "marketCap": 757742336, "fiftyTwoWeekLow": 3.73, "fiftyTwoWeekHigh": 19.18, "priceToSalesTrailing12Months": 26.506536, "fiftyDayAverage": 14.6371, "twoHundredDayAverage": 8.1024, "currency": "USD", "enterpriseValue": 752647744, "floatShares": 35640497, "sharesOutstanding": 53437400, "sharesShort": 3196574, "sharesShortPriorMonth": 3386239, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0598, "heldPercentInsiders": 0.08685, "heldPercentInstitutions": 0.78834, "shortRatio": 2.63, "shortPercentOfFloat": 0.060399998, "impliedSharesOutstanding": 53437400, "bookValue": 1.145, "priceToBook": 12.38428, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -239500992, "trailingEps": -4.95, "forwardEps": -3.06, "enterpriseToRevenue": 26.328, "enterpriseToEbitda": -3.976, "52WeekChange": 1.1199999, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "QURE", "underlyingSymbol": "QURE", "shortName": "uniQure N.V.", "longName": "uniQure N.V.", "firstTradeDateEpochUtc": 1391610600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e051aa7b-edc2-3bc7-a8c8-c2e424dc5a80", "messageBoardId": "finmb_171029664", "gmtOffSetMilliseconds": -18000000, "currentPrice": 14.18, "targetHighPrice": 70.44816, "targetLowPrice": 19.964315, "targetMeanPrice": 35.7966, "targetMedianPrice": 29.455816, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 435240992, "totalCashPerShare": 8.929, "ebitda": -189319008, "totalDebt": 496711008, "quickRatio": 6.181, "currentRatio": 6.512, "totalRevenue": 28587000, "debtToEquity": 889.828, "revenuePerShare": 0.591, "returnOnAssets": -0.16624, "returnOnEquity": -1.4756501, "grossProfits": -154076000, "freeCashflow": -125178000, "operatingCashflow": -179424992, "revenueGrowth": 0.625, "operatingMargins": -17.769129, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]